Compare VELO & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | SAVA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 103.9M |
| IPO Year | N/A | N/A |
| Metric | VELO | SAVA |
|---|---|---|
| Price | $18.13 | $2.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $5.00 |
| AVG Volume (30 Days) | ★ 1.8M | 863.6K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,158,000.00 | N/A |
| Revenue This Year | $11.94 | N/A |
| Revenue Next Year | $56.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.44 | N/A |
| 52 Week Low | $1.43 | $1.15 |
| 52 Week High | $23.84 | $4.98 |
| Indicator | VELO | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.84 |
| Support Level | N/A | $1.97 |
| Resistance Level | N/A | $2.19 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 85.14 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.